CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,820 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01596595
NCT01596595N/ACompleted

Longitudinal Surveillance Study of the 4-SITE Lead/Header System

Boston Scientific Corporation·observational·Posted May 11, 2012·Updated Mar 19, 2021

In Brief

An observational study for Primary Prevention of Sudden Cardiac Arrest and Secondary Prevention of Sudden Cardiac Arrest. Completed, enrolled 1,820 participants across 111 sites in 3 countries.

Detailed Summary

Post-approval studies of implanted leads provide an opportunity to observe and assess patient outcomes and technology performance in a real-world setting. The goal of the study is to evaluate, document and report on the appropriate clinical performance, long-term reliability and the functional integrity of the Boston Scientific ENDOTAK RELIANCE® 4-SITE™ Lead and the pulse generator 4-SITE Header.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, United States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 11, 2012
Enrollment StartApr 4, 2013
Primary CompletionFeb 18, 2020
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 14.1 years ago